The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
List view / Grid view
Filter the results
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.